Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

20071,699 citationsJournal Articlebronze Open Access

Authors

Jan B. Vermorken · Universitair Ziekenhuis Brussel

Éva Remenár · National Institute of Oncology

Carla van Herpen · Radboud University Medical Center

Thierry Gorlia · European Organisation for Research and Treatment of Cancer

Ricard Mesı́a · Institut Català d'Oncologia

M. Degardin · Centre Oscar Lambret

John S. Stewart

Abstract

As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00003888 [ClinicalTrials.gov].).

Topics & Keywords

Head and Neck Cancer Studies Head and Neck Surgical Oncology Ear and Head Tumors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 17, pp. 1695-1704

DOI: 10.1056/nejmoa071028

Field-Weighted Citation Impact: 74.54